Advertisement

Topics

Search Results for "Hydrocodone Bitartrate 7 5 Mg"

21:55 EDT 21st August 2017 | BioPortfolio

Matching Channels

None

Matching News

Lannett Receives Approval For Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg And 10 mg/300 mg

PHILADELPHIA, June 22, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug App...

Hydrocodone Bitartrate Industry Key Players and Market Analysis Says a New Research Report at DeepResearchReports.com

PUNE, India, May 31, 2017 /PRNewswire/ -- Global Hydrocodone Bitartrate Market 2017 Research Report initially provides a basic overview of the industry that covers definition, applications and man...

Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitartrate And Acetaminophen Tablets USP

PHILADELPHIA, June 26, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug App...

Perrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution

DUBLIN, June 19, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched hydrocodone bitartrate and homatropine methylbromide oral solution. Hydrocodone bitart...

Horizon Pharma Announces Four Poster Presentations On PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules At

  Life Sciences Jobs   ...

Evofem Announces First Patient Enrolled In A Phase III Clinical Trial Of AMPHORA (L-Lactic Acid, Citric Acid, And Potassium Bitartrate) For Prevention Of Pregnancy

  Life Sciences Jobs   ...

KemPharm Announces Publication Of Study Of Intranasal Abuse Of Hydrocodone Combination Products In

  Life Sciences Jobs   ...

AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) Receives Qualified Infectious ...

"BV is the most common vaginal infection among women of childbearing age and gonorrhea is the second most commonly reported infectious disease," said Kelly Culwell Read more...

Matching PubMed Articles

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain.

This study evaluated the safety and effectiveness of a once-daily, single-entity, extended-release hydrocodone bitartrate (HYD) among patients with chronic noncancer and non-neuropathic pain who requi...

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.

Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential effect can have significant detrimental ...

A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.

To summarize available clinical evidence for cysteamine bitartrate preparations in the treatment of nephropathic cystinosis as identified through a systematic literature review (SLR).

The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.

In 2012, hydrocodone combination products (HCPs) were the most prescribed medications in the United States. Under the Controlled Substance Act of 1970, hydrocodone alone was classified as a Schedule I...

Hydrocodone, but Neither Morphine nor Oxycodone, Is Effective in Suppressing Burn-Induced Mechanical Allodynia in the Uninjured Foot Contralateral to the Burn.

Opioids are commonly used to treat severe, burn-induced pain. However, there is a lack of rodent studies that examine the differential effects of various opioids on burn pain. The authors recently dem...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement